The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …

Individuals suffering from severe viral respiratory tract infections have recently emerged as
“at risk” groups for developing invasive fungal infections. Influenza virus is one of the most …

Background The biological processes associated with postacute sequelae of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Some patients hospitalized with acute COVID-19 suffer respiratory symptoms that persist for
many months. We delineated the immune-proteomic landscape in the airways and …

Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-
inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients …

Background No effective pharmacological or non-pharmacological interventions exist for
patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for …

Background Evidence suggests a role for excessive inflammation in COVID-19
complications. Colchicine is an oral anti-inflammatory medication beneficial in gout …

Systemic inflammation elicited by sepsis can induce an acute cerebral dysfunction known as
sepsis-associated encephalopathy (SAE). Recent evidence suggests that SAE is common …

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic
variation influences the development of illness requiring critical care or hospitalization,–after …